To determine whether striatal amyloidosis can help predict disease progression in individuals at genetic risk for AD, we sought to examine the tau accumulation relationship with cortical and striatal amyloid, and with memory performance in non-demented individuals with autosomal dominant Alzheimer's disease (ADAD). Thirty-nine (16 carriers aged 28-44, 23 age-matched non-carriers) non-demented individuals from the Colombian kindred (PSEN1 E280A mutation) were evaluated using PiB-PET, Flortaucipir-PET (FTP; tau), and memory testing (CERAD Word List Learning). PiB was measured in Freesurfer-defined cortical and striatal (caudate/putamen) aggregates. FTP was measured in entorhinal and inferior temporal cortices. These findings suggest that striatal amyloid in preclinical ADAD may be more predictive of progression to dementia than cortical amyloid. This study provides insight into the role of striatal amyloid in the progression of AD, and informs the pre-symptomatic treatment trials targeting amyloid in this population.